Skip to main content
OpenTrials
Completed

NCT Number: NCT00480402

Natural Progesterone and Preterm Birth in Twins

To assess the effectiveness of natural progesterone supplementation in preventing preterm births in twins.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Instituto Valenciano de la Infertilidad

Valencia, 46015, Spain

About this study

Objective: To assess the effectiveness of natural progesterone supplementation in preventing preterm births in twins.

Study Design: National multicenter randomized double blind controlled clinical trial.

Setting: Six tertiary hospitals in the east of Spain (communities of Valencia and Murcia): Instituto Universitario IVI Valencia, Hospital Universitario La Fe (Valencia), Hospital Universitario Dr. Peset (Valencia), Hospital General Universitario (Alicante), Hospital Vega Baja de Orihuela (Alicante) y Hospital Virgen de la Arrixaca (Murcia).

Population: 246 bichorionic biamniotic twin pregnant women divided in three groups according to the allocated randomized treatment: (I) placebo (N=82); (II) 200 mg progesterone (N=82); and (III) 400 mg progesterone (N=82).

Methods: All participant women will self-administer two vaginal pessaries at bedtime containing the allocated treatment. Vaginal pessaries will be identical externally but will contain either placebo or 200 mg of natural progesterone (Laboratorios Effik, Madrid, Spain). The treatment will be applied from the 20th week until the 34th week (or until delivery if it occurred earlier). Control visits will be performed at 24, 28, 32 and 34 weeks. Pregnancies will be managed according to each local protocol. An external statistical analysis will be performed on intention to treat basis.

Main outcome measure: Preterm birth rate (<37 weeks). Secondary outcome measures: very preterm birth rate (<32 weeks); cervical length measured by vaginal ultrasound at each control visit; need for tocolytic treatments; rate of preterm premature rupture of membranes; and perinatal morbidity and mortality.

Estimated period of study: 2006-2008.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Bichorionic biamniotic twin pregnant women
  • = or > 18 years old

Exclusion criteria

  • Single pregnancy or monochorionic twin pregnancy or triplets
  • Chronic hepatic pathology, previous alterations in hepatic analysis during anti-contraceptive treatment; or gestational cholestasis in in previous pregnancies.Basal alterations in hepatic analysis profile.
  • Profylactic cerclage until week 14.
  • Basal alterations in renal analysis profile
  • Local allergy to micronized natural progesterone
  • Genital pathology not allowing for correct absorption of medication
  • Fetal anomoly diagnosed after sonograph week 12 and/or 20.
  • Smokers of more than 10 cigarettes/day
  • Consumers of illegal substances

Treatment and study plan

200 mg of Progesterone

Drug

Administration of 200 mg of Progesterone

400 mg Progesterone

Drug

Administration of 400 mg Progesterone

Placebo

Drug

Administration of a Placebo

Sponsors and collaborators

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Other

Registry information

Official study title

Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
May 30, 2007
Registry last updated
Apr 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.